Drs Joseph Mikhael and Sigurdur Y. Kristinsson discuss whether it is time to screen for multiple myeloma and what we can ...

While traditional induction therapy for newly diagnosed stage 2 myeloma often focuses on combinations of proteasome inhibitors, immunomodulatory drugs, and steroids, these newer immunotherapy classes ...

A community-based (real-world) study showed that artificial intelligence (AI)-informed analysis of screening mammograms ...

In this video, Omar Nadeem, MD, an assistant professor of medicine at Harvard Medical School, discusses the factors that impact if or when a patient with multiple myeloma will relapse.

The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies such as chimeric antigen receptor (CAR) T-cell products and antibody-drug ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

In this video, Omar Nadeem, MD, an assistant professor of medicine at Harvard Medical School, discusses improving access to ...

Blenrep® (belantamab mafodotin) has been registered for use in adults with multiple myeloma who have relapsed or become resistant to first-line ...

How Does Darzalex Faspro Work for Multiple Myeloma? Darzalex Faspro is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by ...